| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
|
Ziller, V.
|
|
|
20 |
3 |
p. 431-436
|
artikel
|
| 2 |
Adherence with adjuvant hormonal therapy for breast cancer
|
Ruddy, K.J.
|
|
|
20 |
3 |
p. 401-402
|
artikel
|
| 3 |
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
|
Moreau, M.
|
|
|
20 |
3 |
p. 513-519
|
artikel
|
| 4 |
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
|
Ruan, J.
|
|
|
20 |
3 |
p. 413-424
|
artikel
|
| 5 |
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
|
de Boer, R.
|
|
|
20 |
3 |
p. 486-491
|
artikel
|
| 6 |
Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?
|
Loriot, Y.
|
|
|
20 |
3 |
p. 596-597
|
artikel
|
| 7 |
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)
|
Loprinzi, C.L.
|
|
|
20 |
3 |
p. 542-549
|
artikel
|
| 8 |
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
|
Goy, A.
|
|
|
20 |
3 |
p. 520-525
|
artikel
|
| 9 |
Cancer incidence and mortality in Iran
|
Mousavi, S.M.
|
|
|
20 |
3 |
p. 556-563
|
artikel
|
| 10 |
Cancer risks in Crohn disease patients
|
Hemminki, K.
|
|
|
20 |
3 |
p. 574-580
|
artikel
|
| 11 |
Clustering dietary habits and the risk of breast and ovarian cancers
|
Edefonti, V.
|
|
|
20 |
3 |
p. 581-590
|
artikel
|
| 12 |
Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy
|
Gobbi, P.G.
|
|
|
20 |
3 |
p. 465-468
|
artikel
|
| 13 |
Cut to the chase: on the need for genotype-specific soft tissue sarcoma trials
|
Gupta, A.
|
|
|
20 |
3 |
p. 399-400
|
artikel
|
| 14 |
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
|
Yerushalmi, R.
|
|
|
20 |
3 |
p. 437-440
|
artikel
|
| 15 |
Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial
|
Bono, P.
|
|
|
20 |
3 |
p. 595-596
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
20 |
3 |
p. ii-iii
|
artikel
|
| 17 |
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
|
Bengala, C.
|
|
|
20 |
3 |
p. 469-474
|
artikel
|
| 18 |
High risk of cardiac dysfunction after treatment of secondary acute myeloid leukaemia to breast cancer
|
Willems, L.
|
|
|
20 |
3 |
p. 597-599
|
artikel
|
| 19 |
Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use
|
Furniss, C.S.
|
|
|
20 |
3 |
p. 534-541
|
artikel
|
| 20 |
Increased γ-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast
|
Liu, T.
|
|
|
20 |
3 |
p. 441-448
|
artikel
|
| 21 |
in this issue
|
|
|
|
20 |
3 |
p. 397
|
artikel
|
| 22 |
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
|
McCabe, C.
|
|
|
20 |
3 |
p. 403-412
|
artikel
|
| 23 |
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
|
Italiano, A.
|
|
|
20 |
3 |
p. 425-430
|
artikel
|
| 24 |
Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
|
Ayllon, J.
|
|
|
20 |
3 |
p. 600-601
|
artikel
|
| 25 |
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|
Goekkurt, E.
|
|
|
20 |
3 |
p. 481-485
|
artikel
|
| 26 |
Pharmacokinetics of sunitinib in an obese patient with a GIST
|
Desar, I.M.E.
|
|
|
20 |
3 |
p. 599-600
|
artikel
|
| 27 |
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
|
Antón, A.
|
|
|
20 |
3 |
p. 454-459
|
artikel
|
| 28 |
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer
|
Spitaleri, G.
|
|
|
20 |
3 |
p. 498-502
|
artikel
|
| 29 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
|
Roy, V.
|
|
|
20 |
3 |
p. 449-453
|
artikel
|
| 30 |
Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
|
Hussain, A.
|
|
|
20 |
3 |
p. 492-497
|
artikel
|
| 31 |
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
|
Saad, E.D.
|
|
|
20 |
3 |
p. 460-464
|
artikel
|
| 32 |
Recognition of comorbid diabetes and obesity in hospital records of newly diagnosed cancer patients
|
Polednak, A.P.
|
|
|
20 |
3 |
p. 591-592
|
artikel
|
| 33 |
Reply to Antisense oligonucleotide targeting Bcl-2 mRNA in cancer; bad drug, bad target, neither or both?
|
Palmieri, G.
|
|
|
20 |
3 |
p. 597
|
artikel
|
| 34 |
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
|
Dupuis, J.
|
|
|
20 |
3 |
p. 503-507
|
artikel
|
| 35 |
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
|
Ennishi, D.
|
|
|
20 |
3 |
p. 526-533
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
20 |
3 |
p. iv-v
|
artikel
|
| 37 |
The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy
|
Vazquez-Martin, A.
|
|
|
20 |
3 |
p. 592-595
|
artikel
|
| 38 |
The causes of cancer in France
|
Boffetta, P.
|
|
|
20 |
3 |
p. 550-555
|
artikel
|
| 39 |
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
|
Noy, A.
|
|
|
20 |
3 |
p. 508-512
|
artikel
|
| 40 |
Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis
|
Gondos, A.
|
|
|
20 |
3 |
p. 564-573
|
artikel
|
| 41 |
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
|
Enzinger, P.C.
|
|
|
20 |
3 |
p. 475-480
|
artikel
|
Tijdschrift beschrijving